CAS 315183-21-2
:Procaspase activating compound 1
Description:
Procaspase activating compound 1 (PAC-1) is a small molecule that plays a significant role in the activation of procaspases, which are precursors to caspases involved in the apoptotic pathway. The compound is characterized by its ability to selectively activate procaspase-3, leading to apoptosis in cancer cells, making it a potential therapeutic agent in oncology. PAC-1 is known for its relatively low molecular weight and specific structural features that facilitate its interaction with procaspases. It has been studied for its effects on various cancer cell lines, demonstrating the ability to induce cell death in a caspase-dependent manner. Additionally, PAC-1's mechanism of action involves the stabilization of procaspase-3, promoting its conversion to the active caspase-3 form. This compound is of interest in research focused on cancer treatment, particularly in the context of enhancing the efficacy of existing therapies. However, further studies are needed to fully understand its pharmacokinetics, potential side effects, and overall therapeutic potential in clinical settings.
Formula:C23H28N4O2
InChI:InChI=1S/C23H28N4O2/c1-2-7-20-10-6-11-21(23(20)29)16-24-25-22(28)18-27-14-12-26(13-15-27)17-19-8-4-3-5-9-19/h2-6,8-11,16,29H,1,7,12-15,17-18H2,(H,25,28)
InChI key:InChIKey=YQNRVGJCPCNMKT-UHFFFAOYSA-N
SMILES:C(=NNC(CN1CCN(CC2=CC=CC=C2)CC1)=O)C3=C(O)C(CC=C)=CC=C3
Synonyms:- 1-Piperazineacetic acid, 4-(phenylmethyl)-, 2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide
- 1-Piperazineacetic acid, 4-(phenylmethyl)-, [[2-hydroxy-3-(2-propenyl)phenyl]methylene]hydrazide
- Pac-1
- Pac1
- Procaspase activating compound 1
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
4-(Phenylmethyl)-1-Piperazineacetic Acid-2-[[2-Hydroxy-3-(2-Allyl-1-Yl)Phenyl] Methylene] Hydrazide
CAS:4-(Phenylmethyl)-1-Piperazineacetic Acid-2-[[2-Hydroxy-3-(2-Allyl-1-Yl)Phenyl] Methylene] HydrazidePurity:98%Molecular weight:392.49g/molPAC-1
CAS:<p>PAC-1 (Procaspase activating compound 1) has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer and Thoracic Cancers.</p>Formula:C23H28N4O2Purity:96.78% - 99.77%Color and Shape:SolidMolecular weight:392.49PAC-1
CAS:Controlled Product<p>Applications PAC-1 is a caspase 3 activator. Caspase activation is a key strategy in cancer therapy. Caspase 3 is a key executioner caspase and direct effector of apoptosis. Hallmark of many cancers is the circumvention of signal in the activation of executioner caspases and loss of apoptotic response. EC50 for caspase 3 activation = 0.33 μM and caspase 7= 4.5 μM. The IC50 for apoptosis induction = 0.92 μM. Elevated caspase 3 level in cancerous cell lines and tissues allows PAC-1 to selectively induce apoptosis in tissues.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Slee, E., et al.: J. Biol. Chem., 276, 7320 (2001), Pop, C., et al.: Biochemistry, 42, 12311 (2003), Li, L., et al.: Science, 305, 1471 (2004), Green, D., et al.: J. Clin. Invest., 115, 2610 (2005), Satoh, T., et al.: Clin. Cancer Res., 15, 3872 (2009),<br></p>Formula:C23H28N4O2Color and Shape:NeatMolecular weight:392.49PAC 1
CAS:<p>PAC 1 is a small-molecule apoptosis inducer, derived from synthetic sources, with a unique mode of action targeting the apoptotic pathways in cancer cells. PAC 1 functions by selectively activating procaspase-3, an inactive precursor of the caspase enzymes, which play a crucial role in the execution phase of cell apoptosis. By facilitating the conversion of procaspase-3 to its active form, PAC 1 enhances the apoptotic response in cancer cells, promoting cell death and offering potential therapeutic advantages.</p>Formula:C23H28N4O2Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:392.49 g/mol




